Adults diagnosed with myelodysplastic syndrome or acute myeloid leukemia who carry a multihit TP53 allelic state face an independently elevated risk of developing sepsis compared with those carrying wild-type genes, according to a retrospective cohort study.
Infection represents a leading cause of treatment-related mortality in both myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Concurrently, TP53-mutated myeloid disease has gained increasing recognition for its immunosuppressive characteristics. However, whether the severity of infection depends specifically on the TP53 allelic state, and whether that genetic status could therefore be used to guide supportive care strategies, had remained undefined prior to the investigation.
To evaluate this relationship, investigators retrospectively examined 469 adult patients diagnosed with either MDS or AML at a tertiary medical center between January 2020 and September 2024. The study cohort comprised 236 patients with MDS and 233 patients with AML. Based on genetic profiling, the cohort was classified into three distinct categories: 399 patients with wild-type TP53, 12 patients with a monohit alteration, and 58 patients exhibiting a multihit TP53 allelic state.
The research team assessed all documented infection episodes, sepsis occurrences, and bacteremia developing within one year of diagnosis. To rigorously account for mortality during the one-year follow-up window, cumulative incidence rates were estimated through competing-risk analysis that treated death as a competing event. In addition, independent clinical risk factors for infectious complications were identified through multivariable Cox proportional hazards regression modeling.
Over the one-year observation period, the cumulative incidence of any infection reached 75.9 percent in patients with multihit TP53 status, compared with 62.7 percent in wild-type patients and 41.7 percent in monohit patients, yielding a statistically significant difference (p = 0.0331). The divergence among groups was substantially more pronounced when analyzing sepsis specifically, where multihit patients experienced a one-year cumulative incidence of 37.9 percent compared to 17.3 percent among wild-type patients (p = 0.0008).
On multivariable regression analysis, multihit TP53 status independently predicted sepsis with a hazard ratio of 2.56 (95 percent confidence interval, 1.60 to 4.07; p < 0.001), while failing to independently predict overall infection (hazard ratio 1.30, 95 percent confidence interval, 0.93 to 1.82; p = 0.130). Among patients who contracted an infection, the proportion experiencing sepsis reached 54.5 percent in the multihit group compared to 29.4 percent among wild-type patients (p = 0.0016), an association that appeared most apparent in MDS.
The investigators concluded that biallelic TP53 inactivation is associated less with baseline susceptibility to infection itself than with the progression of an established infection to sepsis. Consequently, incorporating TP53 allelic state into routine infection risk assessment may help medical teams refine antimicrobial prophylaxis and surveillance strategies alongside disease-directed therapy, particularly for patients diagnosed with myelodysplastic syndrome.
Subject of Research: TP53 allelic state and sepsis risk in myeloid neoplasms
Article Title: Multihit TP53 allelic state independently predicts sepsis in myelodysplastic syndrome and acute myeloid leukemia
Article References: Ha, H., Min, S., Kim, S., Heumasse, P. V., Kim, S.-A., Park, S., Kim, Y., Seong, M.-W., Shin, D.-Y., Song, I.-C., Kim, I., & Hong, J. (2026). Multihit TP53 allelic state independently predicts sepsis in myelodysplastic syndrome and acute myeloid leukemia. Supportive Care in Cancer, 34(12), Article 1258. https://doi.org/10.1007/s00520-026-11477-1
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11477-1
Keywords: TP53 mutation, myelodysplastic syndrome, acute myeloid leukemia, sepsis, bacteremia, multihit TP53, biallelic inactivation, monohit TP53, wild-type TP53, immunosuppression, competing-risk analysis, Cox regression, cumulative incidence, antimicrobial prophylaxis, treatment-related mortality, supportive care in cancer
News Source: Nathaniel Bowman. (November 19, 2026). Multihit TP53 Mutations Independently Predict Sepsis in MDS and AML. Scienmag.



